$0.334300
0.038.12%
At Close: -
$0.350000
0.024.70%
After Hours: 7:59 PM EDT
15 minutes delayed
Ginkgo Bioworks Holdings
DNANYSE
Ginkgo Bioworks Holdings (NYSE:DNA) Stock, Analyst Ratings, Price Targets, Predictions
Ginkgo Bioworks Holdings Inc has a consensus price target of $5.14, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from BTIG, Morgan Stanley, and TD Cowen on June 26, 2024, May 15, 2024, and March 1, 2024. With an average price target of $1.4 between BTIG, Morgan Stanley, and TD Cowen, there's an implied 300.00% upside for Ginkgo Bioworks Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
Morgan Stanley
William Blair
TD Cowen
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Ginkgo Bioworks Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2024 | Buy Now | -42.86% | BTIG | Mark Massaro | $0.5 → $0.2 | Maintains | Sell | Get Alert |
| 05/15/2024 | Buy Now | — | BTIG | Mark Massaro | — | Downgrade | Neutral → Sell | Get Alert |
| 05/15/2024 | Buy Now | 185.71% | Morgan Stanley | Tejas Savant | $2 → $1 | Maintains | Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | — | William Blair | Matt Larew | — | Downgrade | Market Perform → Underperform | Get Alert |
| 03/01/2024 | Buy Now | 757.14% | TD Cowen | Steven Mah | $7 → $3 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | 214.29% | Goldman Sachs | Matthew Sykes | $1.25 → $1.1 | Maintains | Sell | Get Alert |
| 01/22/2024 | Buy Now | 214.29% | Goldman Sachs | Matthew Sykes | $1.25 → $1.1 | Maintains | Sell | Get Alert |
| 11/15/2023 | Buy Now | 614.29% | Raymond James | Rahul Sarugaser | → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/14/2023 | Buy Now | 614.29% | Raymond James | Rahul Sarugaser | → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/09/2023 | Buy Now | — | BTIG | Mark Massaro | — | Downgrade | Buy → Neutral | Get Alert |
| 06/05/2023 | Buy Now | 257.14% | Goldman Sachs | Matthew Sykes | $3 → $1.25 | Maintains | Sell | Get Alert |
| 06/02/2023 | Buy Now | 257.14% | Goldman Sachs | Matthew Sykes | $3 → $1.25 | Downgrade | Neutral → Sell | Get Alert |
| 05/11/2023 | Buy Now | — | William Blair | Matt Larew | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/29/2022 | Buy Now | 1614.29% | Berenberg | Gaurav Goparaju | → $6 | Initiates | → Buy | Get Alert |
| 10/04/2022 | Buy Now | 1328.57% | Morgan Stanley | Tejas Savant | → $5 | Initiates | → Equal-Weight | Get Alert |
| 08/16/2022 | Buy Now | 1614.29% | BTIG | Mark Massaro | $5 → $6 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 4042.86% | Raymond James | Rahul Sarugaser | $11.5 → $14.5 | Maintains | Outperform | Get Alert |
| 06/16/2022 | Buy Now | 1142.86% | Jefferies | Laurence Alexander | $11.5 → $4.35 | Maintains | Buy | Get Alert |
| 05/18/2022 | Buy Now | 757.14% | B of A Securities | Derik De Bruin | $6 → $3 | Downgrade | Neutral → Underperform | Get Alert |
| 03/02/2022 | Buy Now | 3328.57% | Cowen & Co. | Steven Mah | → $12 | Initiates | → Outperform | Get Alert |
| 02/23/2022 | Buy Now | 1900% | Goldman Sachs | Matthew Sykes | → $7 | Initiates | → Neutral | Get Alert |
| 02/01/2022 | Buy Now | 1614.29% | B of A Securities | Derik De Bruin | → $6 | Initiates | → Neutral | Get Alert |
| 01/28/2022 | Buy Now | 2185.71% | B of A Securities | Derik De Bruin | → $8 | Initiates | → Buy | Get Alert |
| 01/07/2022 | Buy Now | 3328.57% | BTIG | Mark Massaro | → $12 | Initiates | → Buy | Get Alert |
| 10/13/2021 | Buy Now | 4042.86% | Raymond James | — | — | Initiates | → Outperform | Get Alert |
| 10/12/2021 | Buy Now | — | William Blair | Matt Larew | — | Initiates | → Outperform | Get Alert |
| 09/20/2021 | Buy Now | 3900% | HSBC | Sriharsha Pappu | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Ginkgo Bioworks Holdings (DNA) stock?
The latest price target for Ginkgo Bioworks Holdings (NYSE:DNA) was reported by BTIG on June 26, 2024. The analyst firm set a price target for $0.20 expecting DNA to fall to within 12 months (a possible -42.86% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ginkgo Bioworks Holdings (DNA)?
The latest analyst rating for Ginkgo Bioworks Holdings (NYSE:DNA) was provided by BTIG, and Ginkgo Bioworks Holdings maintained their sell rating.
When was the last upgrade for Ginkgo Bioworks Holdings (DNA)?
There is no last upgrade for Ginkgo Bioworks Holdings
When was the last downgrade for Ginkgo Bioworks Holdings (DNA)?
The last downgrade for Ginkgo Bioworks Holdings Inc happened on May 15, 2024 when BTIG changed their price target from N/A to N/A for Ginkgo Bioworks Holdings Inc.
When is the next analyst rating going to be posted or updated for Ginkgo Bioworks Holdings (DNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.
Is the Analyst Rating Ginkgo Bioworks Holdings (DNA) correct?
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a maintained with a price target of $0.50 to $0.20. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $0.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.